Patent intelligence · BR
BR PI0923819
compostos farmacêuticos
compostos farmacêuticos
Patent details — BR PI0923819
- Jurisdiction
- BR
- Status
- granted
- Grant date
- Nov 19, 2019
- Expiration
- Nov 14, 2039
- Applicant
- BIAL PORTELA & Cª S A [PT]
- CPC classes
- A61K 31/ 33 A I, A61K/314178, A61P 3/ 00 A I, A61P/100
Quick answer
BR PI0923819 (compostos farmacêuticos) is held by BIAL PORTELA & Cª S A [PT]. Status: granted. Granted Nov 19, 2019. Expires Nov 14, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BIAL PORTELA & Cª S A [PT]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 33 A I, A61K/314178, A61P 3/ 00 A I, A61P/100, A61P/104, A61P/108
More from BIAL PORTELA & Cª S A [PT]
Related pharmaceutical patents in our USPTO index.
-
WO 2022081033
OPICAPONE ET LÉVODOPA POUR LE TRAITEMENT DE LA MALADIE DE PARKINSON
granted -
WO 2022025781
DISPERSION SOLIDE D'OPICAPONE
granted -
WO 2021182981
OPICAPONE MICRONISÉE
granted -
WO 2020246903
INHIBITEURS DE DOPAMINE-B-HYDROXYLASE
granted -
AU 2018379646
Dopamine-B-hydroxylase inhibitors
granted -
EP 3515433
DIE BLUT-HIRN-SCHRANKE PASSIERENDE DOPAMIN-B-HYDROXYLASE-INHIBITOREN
granted -
US 2019008774
PHARMACEUTICAL FORMULATIONS COMPRISING NITROCATECHOL DERIVATIVES AND METHODS OF MAKING THE SAME
granted
Frequently asked questions
What is US patent PI0923819?
BR PI0923819 (compostos farmacêuticos) is held by BIAL PORTELA & Cª S A [PT]. Status: granted. Granted Nov 19, 2019. Expires Nov 14, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns BR PI0923819?
BIAL PORTELA & Cª S A [PT] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 21 pharmaceutical patents for this assignee.
When does BR PI0923819 expire?
Our index shows an expiration date of Nov 14, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.